23:54 , Jul 26, 2019 |  BioCentury  |  Product Development

Takeda's deals paint a picture of a turnaround in action

With a spate of new and expanded deals this year, Takeda is not letting its $62 billion dollar takeout of Shire slow its transformation from a traditional small molecule company to a home for edgier,...
00:27 , Jul 11, 2019 |  BC Extra  |  Company News

July 10 Company Quick Takes: I-Mab licenses MacroGenics mAb; plus Mirati-Novartis, Jazz-Redx, Sanofi, Horizon and more

I-Mab gains China rights to enoblituzumab I-Mab Biopharma (Shanghai, China) gained exclusive rights to enoblituzumab from MacroGenics Inc. (NASDAQ:MGNX) in China, Hong Kong, Macao and Taiwan for $15 million up front. MacroGenics is eligible for...
23:50 , Jun 11, 2019 |  BC Extra  |  Company News

June 11 Company Quick Takes: Genmab, Janssen together again on CD38; plus GT Apeiron’s launch; BiomX, Aimmune, Keytruda

Genmab, Janssen partner on next-gen CD38 mAb Genmab A/S (CSE:GEN; Pink:GMXAY) granted Janssen Biotech Inc. an option to HexaBody-CD38, building on the companies' collaboration on multiple myeloma CD38 mAb Darzalex daratumumab. Genmab will fund R&D...
23:46 , Mar 21, 2019 |  BC Week In Review  |  Company News

NICE recommends Darzalex to treat MM, almost two years after European approval

The U.K.'s NICE recommended this month that Janssen Biotech's Darzalex daratumumab be available through the Cancer Drugs Fund as a second-line treatment for relapsed multiple myeloma in combination with bortezomib plus dexamethasone. The European Commission...
02:46 , Feb 28, 2019 |  BC Week In Review  |  Clinical News

Subcutaneous daratumumab non-inferior to IV formulation in Phase III

Genmab A/S (CSE:GEN; Pink:GMXAY) said subcutaneous daratumumab met the co-primary endpoints of non-inferiority to IV daratumumab in the Phase III COLUMBA (MMY3012) trial to treat relapsed or refractory multiple myeloma. Partner Janssen Biotech Inc. told...
20:05 , Feb 25, 2019 |  BC Extra  |  Clinical News

Subcutaneous daratumumab non-inferior to IV formulation in Phase III

Genmab A/S (CSE:GEN; Pink:GMXAY) said subcutaneous daratumumab met the co-primary endpoints of non-inferiority to IV daratumumab in the Phase III COLUMBA (MMY3012) trial to treat relapsed or refractory multiple myeloma. Partner Janssen Biotech Inc. told...
01:35 , Feb 15, 2019 |  BC Week In Review  |  Company News

India's Glenmark spinning out innovative assets into U.S. unit

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) will spin out its innovation business to help accelerate its pipeline towards commercialization. The spinout will be a wholly owned subsidiary based in the U.S and have a new CEO...
21:47 , Feb 14, 2019 |  BC Extra  |  Company News

India's Glenmark spinning out innovative assets into U.S. unit

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) will spin out its innovation business to help accelerate its pipeline towards commercialization. The spinout will be a wholly owned subsidiary based in the U.S and have a new CEO...
18:51 , Feb 7, 2019 |  BC Week In Review  |  Clinical News

Sanofi's isatuximab meets survival endpoint for third-line MM

Sanofi (Euronext:SAN; NASDAQ:SNY) said it will submit regulatory applications to FDA and EMA this half for isatuximab in relapsed or refractory multiple myeloma after the humanized IgG1 mAb against CD38 met the primary endpoint in...
06:00 , Feb 5, 2019 |  BC Extra  |  Clinical News

Sanofi's isatuximab meets survival endpoint for third-line MM

Sanofi (Euronext:SAN; NASDAQ:SNY) said it will submit regulatory applications to FDA and EMA this half for isatuximab in relapsed or refractory multiple myeloma after the humanized IgG1 mAb against CD38 met the primary endpoint in...